The successful delivery of another Phase I clinical trial by the team at Simbec-Orion has resulted in the achievement of a significant milestone for Mission Therapeutics. MTX652 was shown to be well tolerated and safe up to a single dose of 200mg and multiple doses of 100mg once daily for 14 days.
We share the hope that this innovative therapeutic approach will provide future treatments for thus far poorly treated pathologic conditions that may be linked to mitochondrial dysfunction such as kidney disease, neurodegenerative disease, rare mitochondrial diseases, and fibrosis.
Learn more here